TradingKey

Más Datos de Abbott Laboratories Compañía

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.

Información de la empresa

Símbolo de cotizaciónABT

Nombre de la empresaAbbott Laboratories

Fecha de salida a bolsaMar 01, 1937

Director ejecutivoMr. Robert B. Ford

Número de empleados114000

Tipo de seguridadOrdinary Share

Fin del año fiscalMar 01

Dirección100 Abbott Park Road

CiudadABBOTT PARK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064-3500

Teléfono12246676100

Sitio Webhttps://www.abbott.com

Símbolo de cotizaciónABT

Fecha de salida a bolsaMar 01, 1937

Director ejecutivoMr. Robert B. Ford

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.61K

-0.40%

Mr. Philip P. Boudreau

Chief Financial Officer, Executive Vice President - Finance

50.97K

-0.75%

Dr. Robert J. Alpern, M.D.

Independent Director

40.80K

+4.17%

Ms. Nancy Mckinstry

Lead Independent Director

38.72K

+4.41%

Ms. Sally E. Blount, Ph.D.

Independent Director

34.06K

-2.76%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.61K

-0.40%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Diabetes Care

1.83B

17.64%

Core Laboratory

1.18B

11.36%

Adult Nutritionals

1.10B

10.67%

Pediatric Nutritionals

1.04B

10.05%

Key Emerging Markets

965.00M

9.32%

Otro

4.24B

40.96%

Por regiónUSD

Nombre

Ganancia

Proporción

All other Countries

6.19B

59.76%

United States

4.17B

40.24%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Diabetes Care

1.83B

17.64%

Core Laboratory

1.18B

11.36%

Adult Nutritionals

1.10B

10.67%

Pediatric Nutritionals

1.04B

10.05%

Key Emerging Markets

965.00M

9.32%

Otro

4.24B

40.96%

Estadísticas de accionistas

Actualizado: vie., 15 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.88%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Capital International Investors

3.46%

Capital Research Global Investors

2.40%

Otro

74.67%

Accionistas

Proporción

The Vanguard Group, Inc.

9.88%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Capital International Investors

3.46%

Capital Research Global Investors

2.40%

Otro

74.67%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

46.42%

Investment Advisor/Hedge Fund

23.17%

Research Firm

3.60%

Bank and Trust

2.24%

Pension Fund

2.21%

Sovereign Wealth Fund

1.37%

Insurance Company

1.06%

Individual Investor

0.48%

Hedge Fund

0.44%

Otro

18.99%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

4616

1.41B

81.28%

+6.94M

2025Q1

4644

1.42B

81.42%

+12.91M

2024Q4

4535

1.39B

80.22%

+15.89M

2024Q3

4391

1.36B

78.29%

-11.85M

2024Q2

4400

1.36B

78.24%

-7.03M

2024Q1

4402

1.35B

77.67%

-9.71M

2023Q4

4429

1.35B

77.56%

-11.05M

2023Q3

4298

1.34B

77.39%

-25.33M

2023Q2

4297

1.35B

77.60%

-13.55M

2023Q1

4281

1.35B

77.46%

-8.61M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

169.07M

9.72%

+1.18M

+0.70%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

87.82M

5.05%

+752.19K

+0.86%

Mar 31, 2025

State Street Global Advisors (US)

77.66M

4.46%

+497.07K

+0.64%

Mar 31, 2025

Capital International Investors

66.82M

3.84%

-1.15M

-1.69%

Mar 31, 2025

Capital Research Global Investors

50.73M

2.92%

-3.36M

-6.22%

Mar 31, 2025

Geode Capital Management, L.L.C.

36.90M

2.12%

+1.23M

+3.46%

Mar 31, 2025

JP Morgan Asset Management

28.80M

1.66%

+3.67M

+14.58%

Mar 31, 2025

Wellington Management Company, LLP

29.76M

1.71%

+3.37M

+12.77%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

20.98M

1.21%

+626.72K

+3.08%

Dec 31, 2024

Wells Fargo Advisors

15.42M

0.89%

+165.54K

+1.09%

Mar 31, 2025

ETFs relacionados

Actualizado: mar., 2 de sep

Nombre

Proporción

iShares U.S. Medical Devices ETF

16.79%

Goldman Sachs Future Health Care Equity ETF

6.3%

GMO US Quality ETF

5.19%

Invesco Pharmaceuticals ETF

4.64%

Polen Capital Global Growth ETF

4.64%

iShares U.S. Healthcare ETF

4.45%

Proshares Ultra Health Care

4.45%

Health Care Select Sector SPDR Fund

4.38%

AdvisorShares Focused Equity ETF

4.37%

Tema Heart & Health ETF

4.31%

iShares U.S. Medical Devices ETF

Proporción16.79%

Goldman Sachs Future Health Care Equity ETF

Proporción6.3%

GMO US Quality ETF

Proporción5.19%

Invesco Pharmaceuticals ETF

Proporción4.64%

Polen Capital Global Growth ETF

Proporción4.64%

iShares U.S. Healthcare ETF

Proporción4.45%

Proshares Ultra Health Care

Proporción4.45%

Health Care Select Sector SPDR Fund

Proporción4.38%

AdvisorShares Focused Equity ETF

Proporción4.37%

Tema Heart & Health ETF

Proporción4.31%

Dividendos

Un total de 16.46B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 13, 2024

ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 19, 2024

ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 15, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 16, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Dec 15, 2023

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option

Jan 12, 2024

Feb 15, 2024

Jan 11, 2024

Sep 21, 2023

ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 09, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 17, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Dec 09, 2022

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 15, 2022

ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Abbott Laboratories

131.420USD

Abbott Laboratories

131.420

Descripción general

Compañía

Finanzas

Análisis